Mostrar el registro sencillo del ítem
Synthesis, leishmanicidal, trypanocidal and cytotoxic activities of quinoline-chalcone and quinoline-chromone hybrids
dc.contributor.author | Coa, Juan Carlos | |
dc.contributor.author | García, Elisa | |
dc.contributor.author | Carda, Miguel | |
dc.contributor.author | Agut, Raúl | |
dc.contributor.author | Vélez, Iván D. | |
dc.contributor.author | Muñoz, July A. | |
dc.contributor.author | Yepes, Lina M. | |
dc.contributor.author | Robledo, Sara M. | |
dc.date.accessioned | 2017-07-18T10:54:53Z | |
dc.date.available | 2017-07-18T10:54:53Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Coa, J.C., García, E., Carda, M. et al. Med Chem Res (2017) 26: 1405. doi:10.1007/s00044-017-1846-5 | ca_CA |
dc.identifier.issn | 1054-2523 | |
dc.identifier.issn | 1554-8120 | |
dc.identifier.uri | http://hdl.handle.net/10234/168377 | |
dc.description.abstract | We report herein the synthesis and biological activities (cytotoxicity, leishmanicidal and trypanocidal) of six quinoline-chalcone and five quinoline-chromone hybrids. The synthesized compounds were evaluated against amastigotes forms of Leishmania (V) panamensis, which is the most prevalent Leishmania species in Colombia and Trypanosoma cruzi, which is the major pathogenic species to humans. Cytotoxicity was evaluated against human U-937 macrophages. Compounds 8–12, 20, 23 and 24 showed activity against Leishmania (V) panamensis, while compounds 9, 10, 12, 20 and 23 had activity against Trypanosoma cruzi with EC50 values lower than 18 mg mL−1. 20 was the most active compound for both Leishmania (V) panamensis and Trypanosoma cruzi with EC50 of 6.11 ± 0.26 μg mL−1 (16.91 μM) and 4.09 ± 0.24 (11.32 μM), respectively. All hybrids compounds showed better activity than the anti-leishmanial drug meglumine antimoniate. Compounds 20 and 23 showed higher activity than benznidazole, the current anti-trypanosomal drug. Although these compounds showed toxicity for mammalian U-937 cells,they still have the potential to be considered as candidates to antileishmanial or trypanocydal drug development. | ca_CA |
dc.format.extent | 30 p. | ca_CA |
dc.format.mimetype | application/pdf | ca_CA |
dc.language.iso | eng | ca_CA |
dc.publisher | Springer Verlag | ca_CA |
dc.relation.isPartOf | Medicinal Chemistry Research July 2017, Volume 26, Issue 7 | ca_CA |
dc.rights | © Springer Science+Business Media New York 2017 "The final publication is available at Springer via http://dx.doi.org/10.1007/s00044-017-1846-5" | ca_CA |
dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | * |
dc.subject | Leishmaniasis | ca_CA |
dc.subject | Chagas disease | ca_CA |
dc.subject | Antiprotozoal activity | ca_CA |
dc.subject | Quinoline | ca_CA |
dc.subject | Hybrids molecules | ca_CA |
dc.title | Synthesis, leishmanicidal, trypanocidal and cytotoxic activities of quinoline-chalcone and quinoline-chromone hybrids | ca_CA |
dc.type | info:eu-repo/semantics/article | ca_CA |
dc.identifier.doi | http://dx.doi.org/10.1016/j.ejmech.2015.07.018 | |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca_CA |
dc.relation.publisherVersion | https://www.sciencedirect.com/science/article/pii/S0223523415301501 | ca_CA |
dc.audience.educationlevel | ||
dc.type.version | info:eu-repo/semantics/acceptedVersion |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
QUIO_Articles [699]
Articles de publicacions periòdiques